Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

Pasithea Therapeutics today announced safety, tolerability, pharmacokinetic (PK) and preliminary efficacy data from the first 2 cohorts of patients (n=6) in its Phase 1 clinical trial of PAS-004, ...

On Thursday, Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced safety, tolerability, pharmacokinetic (PK), and preliminary ...

In a recent study, researchers used high-throughput drug screening to identify potential therapeutic targets and novel ...

Cancer growth blockers are also called cancer growth inhibitors. They are a type of targeted cancer drug. Our body makes chemicals called growth factors that control cell growth. Cancer growth ...

By taking proteins down the cell’s own degradation pathway instead of the typical inhibition approach, TPD allows researchers to develop successful therapies that address previously undruggable ...

Apoptosis is an evolutionarily conserved cell death pathway that plays a crucial role in maintaining tissue homeostasis, orchestrating organismal development, and eliminating damaged cells.

Prostate cancer remains one of the most prevalent malignancies in men across the world. The American Cancer Society estimates 299,010 new cases and about 35,250 deaths from prostate cancer in the ...

The measures we have taken and continue to take will protect the integrity and sustainability of our migration pathways, reduce fraud and relieve pressures on the housing and health care sectors, ...

BRAF, PIK3CA, and AKT1 genes in cancers that are impacted by the RAS-RAF and PI3K signaling pathways. Those mutations are relevant for the selection and monitoring of therapies for colorectal, ...

NSCLC accounts for approximately 80-85% of lung cancers, with BRAF V600E mutations occurring in about 2% of patients with NSCLC. 3 Understanding the role of the mitogen-activated protein within the ...

The Phase 2 PHAROS trial is an open-label, multicenter, single arm study examining BRAFTOVI + MEKTOVI combination therapy in treatment-naive and previously treated patients with BRAF V600E-mutant ...